Eksempler på brug af Piro på Engelsk og deres oversættelser til Dansk
{-}
-
Medicine
-
Colloquial
-
Official
-
Financial
-
Ecclesiastic
-
Official/political
-
Computer
What is Nobivac Piro?
Why has Nobivac Piro been approved?
Adjuvated solvent for Nobivac Piro.
What is Nobivac Piro used for?
The dinner will be prepared by Tatjana Piro.
He is named Piro and is a few hours old on photo.
What is the risk associated with Nobivac Piro?
Vaccination with Nobivac Piro does not prevent infection.
The kind of a clepto… or nimpho… or piro.
What benefit has Nobivac Piro shown during the studies?
The dinner will be prepared by Tatjana Piro.
Nobivac Piro should not be used in bitches that are pregnant or lactating.
Further one main field study was performed,including dogs of at least six months of age of various breeds who received two injections of Nobivac Piro three weeks apart.
Nobivac Piro is a lyophilisate(freeze-dried pellet) and solvent that are made up into a suspension for injection.
The European Commission granted a marketing authorisation valid throughout the European Union for Nobivac Piro to Intervet International B. V. on 2 September 2004.
Nobivac Piro is a vaccine that contains antigens(proteins) from the parasites Babesia canis and Babesia rossi.
For initial vaccination, Nobivac Piro is given as two 1-ml injections under the skin three to six weeks apart.
Nobivac Piro is used to vaccinate dogs aged six months or older against B. canis, a protozoan(single-celled organism) transmitted by ticks that lives in red blood cells.
The effectiveness of Nobivac Piro has been studied in three laboratory studies in which dogs were vaccinated and then challenged exposed to wild type Babesia.
Nobivac Piro contains small amounts of antigens(soluble parasite antigens) from B. canis and the related species B. rossi that have been extracted from cultures of the parasites in red blood cells.
Nobivac Piro was more effective than placebo at stimulating the production of antibodies: more dogs receiving the vaccine developed antibodies than those receiving placebo.